Current status and future potential of CD123-based targeted therapies for acute leukemia
CD123-targeted therapy represents a promising yet challenging frontier in treating high-risk leukemias. While clinical activity has been demonstrated, especially in BPDCN, therapeutic durability and safety remain hurdles. Precision in antigen targeting, combination strategies, and toxicity management will be critical for successful integration of CD123-directed therapies into standard clinical practice.
Authors
- Ahmed Aribi (ORCID: https://orcid.org/0000-0003-2497-3176)
- A. Stein
- Shukaib Arslan
- Ibrahim Aldoss
Institutions
- City Of Hope National Medical Center (US)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1080/14712598.2025.2608209
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00